Immutep (XTER:YP1A) FCF Yield % : -6.69 (As of May. 14, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Immutep FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Immutep's Trailing 12-Month Free Cash Flow is €-21.99 Mil, and Market Cap is €52.78 Mil. Therefore, Immutep's FCF Yield % for today is -6.69%.

The historical rank and industry rank for Immutep's FCF Yield % or its related term are showing as below:

XTER:YP1A' s FCF Yield % Range Over the Past 10 Years
Min: -25.74 Med: -9.75 Max: -3.95
Current: -6.69

During the past 13 years, the highest FCF Yield % of Immutep was -3.95%. The lowest was -25.74%. And the median was -9.75%.

XTER:YP1A's FCF Yield % is ranked better than
65.19% of 1554 companies
in the Biotechnology industry
Industry Median: -14.38 vs XTER:YP1A: -6.69

Immutep's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Immutep FCF Yield % Historical Data

The historical data trend for Immutep's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep FCF Yield % Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Yield %

Get a 7-Day Free Trial

Immutep Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Immutep's FCF Yield %

For the Biotechnology subindustry, Immutep's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Immutep's FCF Yield % falls into.

Immutep FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Immutep's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-21.953	/	0
	=	N/A%

Immutep's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-3.431	*	4	/	0
	=	N/A%

Immutep FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Immutep FCF Yield % Related Terms

Thank you for viewing the detailed overview of Immutep's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (XTER:YP1A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (XTER:YP1A) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (XTER:YP1A) Headlines

No Headlines